INT109958

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.10
First Reported 2003
Last Reported 2003
Negated 0
Speculated 0
Reported most in Abstract
Documents 1
Total Number 2
Disease Relevance 0.72
Pain Relevance 1.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (CRH, HPSE) carbohydrate metabolic process (HPSE) response to stress (CRH)
extracellular space (CRH) signal transduction (CRH) hydrolase activity, acting on glycosyl bonds (HPSE)
CRH (Homo sapiens)
HPSE (Homo sapiens)
Pain Link Frequency Relevance Heat
addiction 16 100.00 Very High Very High Very High
methadone 10 96.04 Very High Very High Very High
dexamethasone 2 93.56 High High
withdrawal 2 90.00 High High
alcohol 2 87.32 High High
opiate 2 83.92 Quite High
Disease Link Frequency Relevance Heat
Opiate Addiction 4 100.00 Very High Very High Very High
Alcohol Addiction 2 87.32 High High
Stress 2 86.36 High High
Congenital Anomalies 2 25.00 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
To further investigate HPA axis function associated with heroin addiction and its treatment, saline placebo and human corticotropin-releasing factor (hCRF) were administered intravenously in two doses, one dose lower (0.5 microg/kg) and one dose higher (2.0 microg/kg) than the dose used in standard clinical diagnostics (100 microg), to 16 normal male volunteer controls (NV) and eight male stable-dose methadone-maintained former heroin addicts without ongoing drug or alcohol abuse or dependence (MM).
hCRF Binding (associated) of HPA associated with addiction, methadone, opiate addiction and alcohol
1) Confidence 0.10 Published 2003 Journal Neuropsychopharmacology Section Abstract Doc Link 12700714 Disease Relevance 0.36 Pain Relevance 0.73
To further investigate HPA axis function associated with heroin addiction and its treatment, saline placebo and human corticotropin-releasing factor (hCRF) were administered intravenously in two doses, one dose lower (0.5 microg/kg) and one dose higher (2.0 microg/kg) than the dose used in standard clinical diagnostics (100 microg), to 16 normal male volunteer controls (NV) and eight male stable-dose methadone-maintained former heroin addicts without ongoing drug or alcohol abuse or dependence (MM).
corticotropin-releasing factor Binding (associated) of HPA associated with addiction, methadone, opiate addiction and alcohol
2) Confidence 0.09 Published 2003 Journal Neuropsychopharmacology Section Abstract Doc Link 12700714 Disease Relevance 0.36 Pain Relevance 0.73

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox